• The H.C. Wainwright 26th Annual Global Investment Conference is being held on-line and in person, Sept. 9-11.
• Clene management will give a virtual presentation of the company’s most recent achievements and results and will hold one-on-one investor meetings.
• Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering new hope for patients with neurodegenerative conditions.
• The company is seeking FDA approval to file a new drug application for CNM-Au8, using the accelerated approval pathway for treatment of ALS.

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will present at the H.C. Wainwright 26th Annual Global Investment Conference.

During the Sept. 9-11 event, Clene management presented the company’s latest achievements and updates, including recent results and plans for lead candidate CNM-Au8. The company will also participate in one-on-one investor meetings. A webcast of the presentation is available with signup on the “Events” section of the Clene website (https://ibn.fm/IjUxQ).

The unique mechanism of action of CNM-Au8 represents an intersection of innovations from material science and physics, applied to the treatment of neurodegenerative disorders. CNM-Au8, which is taken orally each morning, works by a catalytic mechanism to improve cellular energy production and utilization, a crucial step for maintaining neuronal health. Mitochondrial dysfunction is a common pathway leading to neuronal death in neurodegenerative diseases. By targeting this dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of these conditions.

The company has conducted extensive clinical trials to evaluate the safety as well as the efficacy of CNM-Au8. Two recent independently conducted Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials showed participants saw improvement in survival rates and delays in clinical worsening, defined as first occurrence of death (or death and need for permanent assisted ventilation), tracheostomy, need for invasive ventilatory support, or feeding tube placement.

With over 650 cumulative years of subject exposure, CNM-Au8 has shown a strong safety profile with no serious adverse events linked to the drug. CNM-Au8 hopes to capture a significant share of the therapeutic market for both ALS and MS, by working in conjunction with existing treatments to improve function and increase survival rates.

The company has already submitted CNM-Au8 biomarker and clinical efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a New Drug Application (“NDA”) using the accelerated approval regulatory pathway for ALS. A response is expected in the third quarter of 2024. If this accelerated pathway is approved, the next steps will be to file an NDA by the end of the year and to launch a confirmatory global Phase 3 study in ALS.

Clene’s innovative approach, backed by strong intellectual property with over 150 patents worldwide, positions it as a leader in addressing neurodegenerative diseases. The anticipated FDA interactions and ongoing studies will be crucial steps towards potentially bringing a transformative treatment to patients suffering from these conditions.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

The MoneyShow Income, Growth, & Value Virtual Expo will run from Sept. 17, 2024, to Sept. 19, 2024, on the firm’s dynamic and interactive online platform. Expert speakers will discuss money matters that help attendees safeguard and strengthen their portfolios. The insightful strategies from leading analysts, money managers, economists, and traders will help self-directed investors navigate twists and turns in various asset classes, from stocks to precious metals to alternative investments.

The MoneyShow Virtual Expo series of events appeals to investors looking for assets with the best prices and companies with the strongest growth potential. Investors can visit virtual booths for company presentations and showcases of their prospects and investment opportunities, including selections of short videos. Participants of the Virtual Expo can even win exciting prizes from various exhibitors and MoneyShow, ranging from gift cards to shares of stock.

Traders will also discover new investment opportunities, trends, resources, and financial tools. All content is in the form of downloadable files that can be compiled in a digital briefcase. The event will feature growth-stage and investment-ready companies pitching their businesses among the industry money experts.

Meanwhile, discussion panels and keynote speaker sessions will be conducted by industry dignitaries. They will offer attendees invaluable advice on steering their investment portfolios in the right direction. Attendees can pick up the latest news and current research to get a fresh perspective on the markets.

At the LIVE presentations, experts solve audience queries and offer sound investment tips. Attendees can directly connect with those experts and their fellow investors to expand their networks and discuss financial topics. Investors and executives can also fix one-on-one meetings to understand each other’s requirements, goals and visions.

To learn more, please visit https://ibn.fm/pbi4d.

• Exploration is an important step in finding minerals so they can be potentially mined.
• Renforth Resources is actively involved in gold and mineral exploration through several Canada-based projects.
• An update regarding the company’s Malartic Metals Package Project includes a report on the mapping and prospecting work done at the project.

Minerals are key elements of daily life, and the exploration and supply of minerals are essential. Renforth Resources (CSE: RFR) (OTCQB: RFHRF) is an active mineral exploration company engaged in the exploration and development of its wholly owned, multicommodity mineral properties, which are located in Canada.

“Nearly everything we use each day began life as a mineral,” states a Resources Victoria article (https://ibn.fm/8jBSN). “Your car, PC, mobile phone and power supply are all made with materials derived from minerals.

“Exploration is an important step in finding minerals so they can be potentially mined,” the article continued. “Our demand for minerals is increasing; for example, we need more copper to build renewable energy assets such as wind turbines. This demand is helping drive an increase in exploration.”

Renforth Resources is committed to helping meet the demand. Among the projects the company is working on is its Malartic Metals Package Project (https://ibn.fm/lvxs2), which is comprised of 540 mining claims, totaling more than 30,327 hectares, south of the town of Cadillac, Quebec. The project is contiguous to the Canadian Malartic Mine, the second-largest operating gold mine in Canada and one of the world’s largest gold-mining operations (https://ibn.fm/pYjJZ).

This property is wholly owned, with only the typical requirements to keep the property in good standing, Renforth reports. It is also almost entirely unencumbered with the exception of a handful of claims in the northeastern portion of the property, which are subject to a net smelter return (“NSR”). However, the company points out, there is no known mineralization on those claims, and they are removed from any of the areas of current interest.

“The current property was assembled in 2020 by adding claims to Renforth’s Malartic West property by map staking,” the company states. “The goal of the map staking was to acquire historic gold and base metal showings . . . as well as the pronounced magnetic anomalies joining several of the areas of discrete historic exploration. This is the first time this property has been assembled as it is today and actively explored — a significant portion of the property has never been explored.”

The company’s most recent update reflected mapping and prospecting work and noted that the project is known to “host several occurrences of nickel/cobalt/zinc/copper polymetallic mineralization over >29 km of strike as well as numerous pegmatites prospective for lithium, with elevated lithium also occurring in the Pontiac sediment host rock” (https://ibn.fm/DwSHF).

The update noted several highlights, including prospecting that showed two new locations of surface nickel polymetallic (nickel/cobalt/zinc/copper) mineralization, similar to that seen within the Victoria system. One area is located north of the Lalonde system and one south of the Victoria system, with a total of four places where the polymetallic mineralization comes to surface. The update also reported elevated lithium found in lithium/cesium/tantalum fractionated pegmatites and in the Pontiac sediments, which appears to indicate proximity to blind pegmatites and may represent the mobility of lithium, offering an exploration vector. In addition, the update observed that Victoria drilling has commenced, with two holes completed for a total of 561m and mineralization successfully intersected in both infill holes, with positive results definitively extending mineralization across a drilling gap; the mineralization has now been drilled along a 2.5km length from the road to the west within the 20km-long structure.

Renforth is a battery metals area play with the dominant brownfield land position south of the world class Cadillac-Larder Lake Fault in the prolific Cadillac and Malartic mining camps of Quebec’s Abitibi. Offering exposure to gold, zinc, nickel, copper, cobalt and more, including lithium, Renforth’s land position encompasses several areas of interest.

For more information about the company, visit www.RenforthResources.com.

NOTE TO INVESTORS: The latest news and updates relating to RFHRF are available in the company’s newsroom at https://ibn.fm/RFHRF

MoneyShow’s annual Canadian investor and trader conference will run Sept. 13, 2024, through Sept. 14, 2024, at the Metro Toronto Convention Centre North. The theme of the 2024 event is “Outlook 2024-2025: Politics, Policy, & Profits” and it will feature more than 60 of North America’s top money experts.

They will be participating in two days of networking, discussions, presentations, and training workshops – as well as meet-and-greets, book signings, and a networking reception. More than 2,500 have already registered to attend the prestigious event.

The speakers gracing the event floor are eminent dignitaries with years of experience and proven financial strategies. They will conduct keynote presentations and workshops providing invaluable expertise to strengthen and safeguard one’s portfolio.

Points of discussion at this year’s event include:

• Ways to increase portfolio returns against the backdrop of upcoming elections in the U.S. and Canada.
• How to invest in gold, copper, oil, and other commodities.
• Best stock and options trading strategies for maximum profit and income.
• Tax and financial planning amidst key policy shifts.
• Real estate opportunities given current and future market trends.
• The most lucrative ETFs and stocks for investment.

MoneyShow has 43 years of experience in bringing traders and investors together and connecting them with top thought leaders in common forums. The firm hosts in-person conferences and online expos where financial experts offer sound advice that helps entrepreneurs, companies and investors maximize profits and minimize risks. Attendees at MoneyShow conferences stay up-to-date with the latest news, financial tools and data on investing opportunities and trading strategies.

To learn more, please visit https://ibn.fm/pbi4d

• “Canada’s minerals and metals are essential contributors to our economy, infrastructure, innovation and environmental stewardship,” report states.
• Renforth Resources provided an update on completed summer exploration activities as well as those set to begin.
• “Our team is delivering on multiple fronts with success in the field, laying the groundwork for our winter exploration season,” states CEO.

In the wake of the Canadian government acknowledging the importance of the country’s minerals and metals (https://ibn.fm/jTJBw), Renforth Resources (CSE: RFR) (OTCQB: RFHRF) is providing an update on its exploration activities. The Canada-based mineral exploration company is engaged in the acquisition, exploration and development of mineral properties throughout the country.

“Canada’s minerals and metals are essential contributors to our economy, infrastructure, innovation and environmental stewardship,” the government stated in a Natural Resources Canada release. “And as the world moves toward net zero by 2050, demand for Canada’s mineral resources, especially critical minerals, will only increase. By making the right investments in the exploration and mining sector, we can enable sustainable resource development, create good jobs, drive economic growth and advance Indigenous participation and leadership in our economy.”

In the same release, government officials announced federal investments of more than $15 million in projects to increase Indigenous participation and support the development of Canada’s critical minerals sector.

With that as a backdrop, Renforth Resources has provided a status update. The report includes summer exploration activities that have been completed as well as those set to begin on the company’s wholly owned Malartic Metals Package property and its wholly owned Parbec gold deposit; both properties are located in Malartic, Quebec (https://ibn.fm/zFCyy).

“I am pleased to update fellow shareholders on our completed and ongoing exploration efforts, which touch almost all our wholly owned mineral assets,” said Renforth Resources president and CEO Nicole Brewster in the press release. “Our team continues to develop our understanding of our Beaupr copper discovery, testing its size on surface under cover, and we have commenced testing mineralized material from our Victoria polymetallic system for suitability for preconcentration in a processing flow sheet, funded by the government of Quebec.

“We are also once again working on our Parbec gold deposit, testing our new understanding of the structure and identifying a location to strip the overburden in order to commence bulk/metallurgical test work,” Brewster continued. “Our team is delivering on multiple fronts with success in the field, laying the groundwork for our winter exploration season.”

Renforth is a battery metals area play with the dominant brownfield land position south of the world-class Cadillac-Larder Lake Fault in the prolific Cadillac and Malartic mining camps of Quebec’s Abitibi. Offering exposure to gold, zinc, nickel, copper, cobalt and more, including lithium, Renforth’s land position encompasses several areas of interest.

Renforth’s position is unique in that both the battery metals mineralization within the Malartic Metals Package (“MMP”) and its gold deposit at Parbec are road accessible, with hydro power crossing the property, in an established and secure mining jurisdiction, which regularly ranks in the world’s top 10 (as determined by the Fraser Institute).

For more information about the company, visit www.RenforthResources.com.

NOTE TO INVESTORS: The latest news and updates relating to RFHRF are available in the company’s newsroom at https://ibn.fm/RFHRF

• Nightfood Holdings has strategically entered the human assist solutions market by acquiring Future Hospitality Ventures, a pioneer in robotic solutions for the hospitality industry
• The RaaS model offers cost efficiency, flexibility and simplified adoption, making it a lifeline for businesses facing existential threats due to labor shortages and rising operating costs.

The hospitality industry is undergoing a reckoning driven by out-of-control labor costs. Advancements in technology, such as Robotics-as-a-Service (“RaaS”), present the only viable way forward. This model allows food service and hospitality businesses to access cutting-edge service robots on a subscription basis, bypassing the prohibitive upfront costs that currently prevent many companies from being able to capitalize on the robotics revolution.

Nightfood Holdings (OTCQB: NGTF) recognized the existential crisis facing foodservice businesses in California, the world’s fifth largest economy. The company has strategically positioned itself as a pioneer in RaaS by acquiring Future Hospitality Ventures, a provider of robotic solutions on a subscription basis.

Nightfood’s Strategic Leap into RaaS

Nightfood Holdings’ acquisition of Future Hospitality Ventures marks a significant milestone in its growth trajectory. Future Hospitality is growing its brand, RoboOp365, with innovative robotic solutions that solve the most critical challenges in the hospitality industry: labor shortages, rising operating costs, and insatiable consumer demand for outstanding service experiences. This acquisition aligns perfectly with Nightfood’s commitment to innovation and shareholder value, positioning the company at the forefront of technological advancements in the sector.

Key Robotics-as-a-Service Solutions:

• Front-End Service Robots: Future Hospitality’s service robotics are designed to complement human staff. They help with heavy lifting, reducing work related injuries, and help with other mundane repetitive tasks that do not require human labor. They ensure faster and reliable service delivery. These robots help streamline operations, minimize wait times for customers, and reduce human errors. This allows team personnel to focus on high-leverage, high value interpersonal engagements to truly provide a hospitable experience guests expect.
• Back-End Kitchen Bots: The smart cooking bots offered by Future Hospitality revolutionize kitchen operations by ensuring consistent food quality and enabling anyone to make delicious meals quickly and efficiently. This technology resolves critical issues in busy kitchens, such as the requirement of training and hiring skilled cooks, food quality inconsistency and the strain of labor shortages and high labor costs.

The Broader Impact: RaaS as a Game-Changer

There’s an ongoing revolution making automation a necessity in the hospitality industry. Unfortunately, the high cost of robotics purchases and ownership has prevented many operators from being able to afford the investment in automation. Robotics-as-a-Service has emerged to fill that void, allowing operators and franchisees a lifeline to remaining viable.

RaaS Benefits:

• Cost Efficiency: By offering robots on a subscription basis, RaaS lowers the financial costs of entry for businesses of all sizes, making it easy to manage and maintain, while financially feasible.
• Scalability: RaaS allows businesses to scale their robotic workforce based on occupancy and specific needs, easily allow food service operators to scale based on business performance and adapt to seasonality fluctuations.  

Nightfood is not alone in its quest to disrupt the hospitality market, as we’re witnessing the birth of what projects to be a multi-billion-dollar industry in just a few short years.

Competition breeds excitement, which helps spotlight the entire movement and inspire investment. Alphadroid, for instance, is aiming to create accessible and user-friendly robotic solutions that empower human workers by taking over routine and physically demanding tasks. This aligns with the broader industry trend towards automation, driven by the need to address tasks which can easily be supported.

The transition to robotic solutions that assist workers by taking over routine tasks can be crucial to a pivotal change within service. For instance, “Sunny,” a robot server at Denny’s in Laurel, Maryland, helps reduce the workload during busy hours, allowing human staff to focus on more complex tasks. This example illustrates how robotics can enhance efficiency and job satisfaction when integrated thoughtfully.

The Future of Hospitality and Nightfood’s Role

Many experts believe we’ve already crossed the tipping point. The future of hospitality is written, and that future includes integrated robotics solutions. The remaining questions involve the pace of adoption and who will get left behind.

Future industry economics simply will not work without the efficiency of automation integrated into workflows. Between today and that inevitability, RaaS is the mechanism that allows the hospitality and foodservice industries to transition seamlessly into that future.

As industries pivot, changes must be made to secure efficiency and enrichment. RaaS has become a standard practice, offering a scalable task solution that enhances operations and human revision. Repetitive tasks currently performed by labor has transitioned into an improved service quality due to RaaS working harmoniously with human teams.

Nightfood Holdings’ strategic acquisition of Future Hospitality Ventures positions the company at the forefront of this technological revolution. By leveraging RaaS, Nightfood is not only addressing immediate industry challenges, but also encouraging its long-term growth and success.

As the RaaS market continues to grow, Nightfood’s investment in Future Hospitality Ventures is likely to yield significant returns. The company believes it can establish a competitive edge in the market with external forces necessitating automation and technological innovation. Through these strategic initiatives, Nightfood is not only driving significant value for its shareholders but also playing a pivotal role in shaping the future of the hospitality industry.

For more information, visit the company’s website at https://nightfood.com/

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• SuperCom Ltd., a secure solutions provider for the e-Government, IoT and Cybersecurity sectors, capitalizes on its proprietary technology suite and experienced 24/7 services to help government clients track and identify individuals under legal supervision
• The Israel-based company is focused on public safety through the monitoring of parolees and probation orders, domestic violence suspects and substance abuse rehabilitation patients
• SuperCom has reported a number of new contracts in the United States and Europe this year, helping the company to recognize record gross profit growth and a move into positive territory for its bottom line
• The offender-tracking industry provides value to society not only through security solutions, but also by reducing criminal recidivism and helping offenders to continue functioning as productive employees and family members

The growth and vitality of electronic monitoring (“EM”) technology innovator SuperCom (NASDAQ: SPCB) is reflected in the growing list of new contracts the company continues to secure, including a recently reported technology and service provision contract for an agency located near the nation’s capital.

The contract with the Baltimore-based client covers the deployment of SuperCom’s advanced GPS technology as well as its 24/7 monitoring center services. SuperCom is enhancing the service provider’s ability to legally track the movements of individuals under court-authorized supervision, such as parolees or domestic violence suspects.

“Our GPS technology and 24/7 monitoring center services are perfectly aligned to meet the needs of their clients and operations, providing robust and reliable solutions to support their mission,” SuperCom President and CEO Ordan Trabelsi stated in an Aug. 29 news release (https://ibn.fm/7qJeA). “This contract not only strengthens our footprint in the U.S. market but also reaffirms our commitment to delivering top-tier technology and services that empower our partners and clients to achieve their goals.”

Since the beginning of the year, SuperCom has announced millions of dollars in new orders from European clients on a recurring revenue basis, as well as new contracts with agencies in the United States. That includes a contract announced last month with multiple West Virginia sheriff agencies to leverage SuperCom’s PureOne technology suite for monitoring solutions in rural areas with limited cellular coverage (https://ibn.fm/nImq2).

The contract in Maryland is estimated to generate an annual recurring revenue of about $250,000 for oversight and management of offenders in the criminal justice system.

SuperCom draws on the experience of employees with the nation’s defensive technologies, giving the company an added advantage in the EM security sector. The company’s growing gross profit margins are evident in its most recent quarterly report, in which SuperCom’s executive team noted a Q2 surge in gross profit (65.2%) for a new company record, with net income growth of 183% over the previous quarter and EBITDA improving by 182% during the first half of the year.

“Our strategic focus on cost optimization and capital management, combined with our innovative approach to technology deployment, has driven a significant turnaround in our bottom line,” Trabelsi stated (https://ibn.fm/LZlOS). “Particularly noteworthy is our successful displacement of long-time incumbents in the judicial sector, showcasing the superiority of our PureOne technology. … We are excited about the opportunities ahead and believe in our ability to maintain our momentum.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• With a focus on improving mitochondrial health, CNM-Au8^® stands out among other therapies by targeting the nicotinamide adenine dinucleotide pathway to restore and protect neurological function.
• Nearly 2 million Americans are affected by amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”) or Parkinson’s disease.
• The global therapeutics markets for neurogenerative diseases are projected to grow substantially, driven by the growing prevalence of these conditions, rising geriatric population and the emergence of new therapies.
• Clene is preparing Phase 3 trials of CNM-Au8 in MS and ALS.

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is making significant strides with its lead candidate, CNM-Au8. This innovative treatment focuses on targeting the nicotinamide adenine dinucleotide (“NAD+”) pathway, which is critical for many mitochondrial functions, including energy production and redox homeostasis. Through this novel mechanism, CNM-Au8 restores and protects neurological function, offering new hope for patients with conditions like amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”) and Parkinson’s disease.

The potential market impact of CNM-Au8 is considerable, given the prevalence of these disorders. Approximately 5,000 Americans are diagnosed with ALS each year, and about 30,000 people are currently living with the disease in the U.S. alone, according to CDC statistics (https://ibn.fm/iMM9N). The global market for ALS therapeutics was valued at $537.2 million in 2018 and is expected to grow at a compound annual growth rate (“CAGR”) of 5.8% from 2019 to 2026, driven by increasing awareness, rising geriatric population and increasing incidence rate (https://ibn.fm/MgLWn). According to the National Institute of Neurological Disorders and Stroke, following gradual paralysis, patients with ALS often die from respiratory failure within 3-5 years.

MS, affecting nearly 1 million Americans and an estimated 2.9 million people worldwide, represents an even larger market. MS is a chronic disease that impacts the central nervous system, leading to a wide range of neurological symptoms. The MS therapeutics market is expected to grow significantly, expanding from $25.94 billion in 2023 at a CAGR of 5.9% from 2024 to 2030, fueled by advancements in treatment options and increased diagnostic rates (https://ibn.fm/ZHca3).

Parkinson’s disease, another key target for CNM-Au8, affects nearly 1 million people in the U.S., with 90,000 new cases diagnosed annually, and more than 10 million people worldwide (https://ibn.fm/UhyZV). The global Parkinson’s therapeutics market was valued at $4.28 billion in 2021 and is expected to expand at a CAGR of 12.1% from 2022 to 2030, driven by the increasing geriatric population, which is exposed to a high risk of developing Parkinson’s and the strong product pipeline of disease-modifying therapies (https://ibn.fm/lDbUs).

The potential of CNM-Au8 in these markets is underscored by its mechanism of action. CNM-Au8 works by improving cellular energy production and utilization, crucial for maintaining neuronal health. Mitochondrial dysfunction is a common pathway leading to neuronal death in neurodegenerative diseases. By targeting this dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of these debilitating conditions, providing a dual benefit that could distinguish it from existing therapies.

Clene’s advancement in this field comes at a time when the demand for innovative treatments is surging. The company is now seeking FDA feedback on a potential pathway for accelerated approval for ALS with CNM-Au8, while preparing for Phase 3 clinical trials in both ALS and MS. Driven by encouraging results in clinical trials so far and a robust safety profile with no serious adverse effects, Clene is well-positioned to make significant strides in this therapeutic landscape.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

More Than 60 Top Financial Experts Converging on the Metro Toronto Convention Centre North from Sept. 13-14 for MoneyShow’s “Outlook 2024-2025: Politics, Policy, & Profits” Conference

Canadian investors have had several reasons to celebrate in 2024. They include new stock market highs at home and abroad…strength in select commodities, including a move to record highs in gold…and interest rate cuts now underway domestically and globally.

Yet many questions remain. How will potential political regime shifts in Canada and the U.S. over the coming year impact their portfolios? What will changes in tax law and government programs mean for stocks and bonds? How many more times will the Bank of Canada cut rates – and what will that mean for key commodities and real estate markets?

At the MoneyShow Toronto, attendees will get the answers to all those questions and more – from dozens of North America’s leading money managers, market strategists, economists, trading educators, and acclaimed authors and columnists. They will also receive insights, guidance and recommendations for their stocks, ETFs, options, commodities, real estate, cryptocurrencies, and more.

Select keynote speakers include Larry Berman, Raghav Mehta, Eric Nuttall, Prerna Mathews, Dylan Smith, Brian Belski, and Peter Boockvar. They represent firms such as ETF Capital Management, Fidelity Canada, Ninepoint Partners LP, Mackenzie Investments, Rosenberg Research, BMO Capital Management, and Bleakley Financial Group.

More than 2,500 individuals have already registered to attend. They will enjoy two full days of presentations, panel discussions and workshops like “Stocks, Commodities, & the Economy: Where Things Stand, Where We’re Headed”…“Our Energy Realities and the Multi-Year Bull Market in Energy Stocks”…“The Only Way Is Down: Positioning for the Next Phase of the Cycle”…“Investing in the Growth Engine of the World—The Technology Arena”…and “How to Use Social Sentiment to Profit in Markets.”

MoneyShow will also host an interactive and entertaining TSX closing bell ceremony Friday, Sept. 13, sponsored by the TMX Group Ltd. (TSE: X). Plus, financial advisors will have access to a special conference track of FA-focused workshops, produced in conjunction with the Financial Planning Association of Canada and MoneySense.

The 2024 MoneyShow Toronto

Theme: Outlook 2024-2025: Politics, Policy, & Profits

Organizer:  MoneyShow

Start: Sept. 13, 2024, 9:25 a.m. Eastern

End: Sept. 14, 2024, 5:15 p.m. Eastern

Address:

Metro Toronto Convention Centre North

255 Front Street West

Toronto, ON

M5V 2W6

Price: FREE

Email: customerservice@moneyshow.com

• Lexaria, a global innovator in drug delivery platforms, has just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study
• Two formulations from the study posted outstanding performance, with each utilizing the company’s patented DehydraTECH(TM) technology
• DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) posted blood sugar level reductions of 2.50%, 1.90%, and 1.53%, respectively
• These results build on the positive results from Lexaria’s 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that got no treatment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study (the “study”). This study will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination . The ongoing study uses diabetic, pre-conditioned Zucker rats, falling in one of three study arms, with dosing lasting 12 weeks (https://ibn.fm/uuLLk).

Two formulations posted outstanding performance from the study as of day 56 – DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B). Most notably, they each posted blood sugar level reductions of 2.50%, 1.90%, and 1.53% respectively. DehydraTECH-liraglutide specifically saw a -2.08% change as of day 28 and a -2.50% change as of day 56 in what Lexaria’s management described as “extremely interesting.”

For Lexaria, these results build on the positive results from its 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that received no treatment. For the current study, each of the eight active groups of animals either experienced a smaller increase or an actual decrease in blood sugar level relative to baseline compared to the obese control group in the previous study.

The ongoing study featured eight groups. Groups A through D were administered with different DehydraTECH-CBD compositions. Groups E and F utilized reformulated Rybelsus DehydraTECH compositions, whereas groups G and G used pure glucagon-like peptide-1 (“GLP-1”) drugs semaglutide and liraglutide respectively in DehydraTECH compositions. Additional results from this study are expected soon. However, Lexaria’s management remains optimistic that it will replicate both the interim and previous results, ultimately demonstrating the superiority of its DehydraTECH technology.

The global diabetes treatment market was valued at $79.25 billion in 2023. It is projected that by 2032, it will have surpassed $153 billion in valuation, mainly influenced by the growing prevalence of the condition and the increasing demand for effective drug therapies (https://ibn.fm/1mEgi). For the longest time, treatment options have involved painful injections, which, to many, have been a source of discomfort and, to some, an outright deterrent. Lexaria looks to carve out a piece of the diabetes treatment market share by offering an oral alternative and is banking on its DehydraTECH technology to achieve that. Its previous and ongoing studies are a testament to its commitment to this goal and its pledge to creating shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX